A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature.

IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY
Brain Tumor Pathology Pub Date : 2022-04-01 Epub Date: 2022-01-11 DOI:10.1007/s10014-021-00423-0
Theo F J Kraus, Christoph Schwartz, Lukas Machegger, Barbara Zellinger, Dorothee Hölzl, Hans U Schlicker, Johannes Pöppe, Barbara Ladisich, Mathias Spendel, Michael Kral, Karl Sotlar
{"title":"A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature.","authors":"Theo F J Kraus,&nbsp;Christoph Schwartz,&nbsp;Lukas Machegger,&nbsp;Barbara Zellinger,&nbsp;Dorothee Hölzl,&nbsp;Hans U Schlicker,&nbsp;Johannes Pöppe,&nbsp;Barbara Ladisich,&nbsp;Mathias Spendel,&nbsp;Michael Kral,&nbsp;Karl Sotlar","doi":"10.1007/s10014-021-00423-0","DOIUrl":null,"url":null,"abstract":"<p><p>Here, we report on a patient presenting with two histopathologically distinct gliomas. At the age of 42, the patient underwent initial resection of a right temporal oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade II followed by adjuvant radiochemotherapy with temozolomide. 15 months after initial diagnosis, the patient showed right hemispheric tumor progression and an additional new left frontal contrast enhancement in the subsequent imaging. A re-resection of the right-sided tumor and resection of the left frontal tumor were conducted. Neuropathological work-up showed recurrence of the right-sided oligodendroglioma with features of an anaplastic oligodendroglioma WHO Grade III, but a glioblastoma WHO grade IV for the left frontal lesion. In depth molecular profiling revealed two independent brain tumors with distinct molecular profiles of anaplastic oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade III and glioblastoma IDH wildtype WHO grade IV. This unique and rare case of a patient with two independent brain tumors revealed by in-depth molecular work-up and epigenomic profiling emphasizes the importance of integrated work-up of brain tumors including methylome profiling for advanced patient care.</p>","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":"39 2","pages":"111-119"},"PeriodicalIF":2.7000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090705/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Tumor Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10014-021-00423-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Here, we report on a patient presenting with two histopathologically distinct gliomas. At the age of 42, the patient underwent initial resection of a right temporal oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade II followed by adjuvant radiochemotherapy with temozolomide. 15 months after initial diagnosis, the patient showed right hemispheric tumor progression and an additional new left frontal contrast enhancement in the subsequent imaging. A re-resection of the right-sided tumor and resection of the left frontal tumor were conducted. Neuropathological work-up showed recurrence of the right-sided oligodendroglioma with features of an anaplastic oligodendroglioma WHO Grade III, but a glioblastoma WHO grade IV for the left frontal lesion. In depth molecular profiling revealed two independent brain tumors with distinct molecular profiles of anaplastic oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade III and glioblastoma IDH wildtype WHO grade IV. This unique and rare case of a patient with two independent brain tumors revealed by in-depth molecular work-up and epigenomic profiling emphasizes the importance of integrated work-up of brain tumors including methylome profiling for advanced patient care.

Abstract Image

Abstract Image

Abstract Image

2例胶质瘤患者,具有独立的少突胶质细胞瘤和胶质母细胞瘤生物学,dna甲基化分析证实:病例报告和文献复习。
在这里,我们报告一个病人表现出两个组织病理学上不同的胶质瘤。42岁时,患者接受了IDH突变1p/19q共同缺失WHO II级的右侧颞叶少突胶质细胞瘤的初始切除术,随后使用替莫唑胺辅助放化疗。初次诊断15个月后,患者显示右半球肿瘤进展,在随后的成像中显示新的左额叶对比增强。行右侧肿瘤再切除及左侧额部肿瘤切除。神经病理检查显示右侧少突胶质细胞瘤复发,其特征为间变性少突胶质细胞瘤WHO III级,但左侧额叶病变为胶质母细胞瘤WHO IV级。深入的分子分析揭示了两个独立的脑肿瘤,它们具有不同的分子谱,分别是间变性少突胶质细胞瘤IDH突变1p/19q共同缺失WHO III级和胶质母细胞瘤IDH野生型WHO IV级。这一独特而罕见的病例,通过深入的分子检查和表观基因组分析发现了两个独立的脑肿瘤患者,强调了包括甲基组分析在内的脑肿瘤综合检查对晚期患者护理的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Brain Tumor Pathology
Brain Tumor Pathology 医学-病理学
CiteScore
5.40
自引率
9.10%
发文量
30
审稿时长
>12 weeks
期刊介绍: Brain Tumor Pathology is the official journal of the Japan Society of Brain Tumor Pathology. This international journal documents the latest research and topical debate in all clinical and experimental fields relating to brain tumors, especially brain tumor pathology. The journal has been published since 1983 and has been recognized worldwide as a unique journal of high quality. The journal welcomes the submission of manuscripts from any country. Membership in the society is not a prerequisite for submission. The journal publishes original articles, case reports, rapid short communications, instructional lectures, review articles, letters to the editor, and topics.Review articles and Topics may be recommended at the annual meeting of the Japan Society of Brain Tumor Pathology. All contributions should be aimed at promoting international scientific collaboration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信